Recombinant Rat Proteinase-activated receptor 2 (F2rl1)

What is Proteinase-activated receptor 2 (F2rl1) and what are its key characteristics?

Proteinase-activated receptor 2 (F2rl1), commonly known as PAR2, is a member of the G-protein coupled receptor 1 protein family that functions as a receptor for trypsin and trypsin-like enzymes coupled to G proteins. In rats, as in humans, PAR2 is widely expressed in various tissues with particularly high levels in the pancreas, liver, kidney, small intestine, and colon . The protein is localized in the cell membrane and plays significant roles in multiple physiological and pathological processes including inflammation, fibrosis, and hypertrophy . PAR2 has several synonyms including CFIIRL1, F2RL1, GPCR11, coagulation factor II receptor-like 1, G-protein coupled receptor 11, and proteinase-activated receptor 2 .

How does rat PAR2 compare structurally and functionally to human PAR2?

While the search results don't provide specific comparative data between rat and human PAR2, research has identified that the rat PAR2 gene has orthologs in multiple species including mouse, human, bovine, frog, chimpanzee, and chicken . The functional conservation across species makes rat PAR2 a valuable model for studying mechanisms potentially applicable to human physiology and pathology. In experimental settings, rat PAR2 (UniProt: Q63645) serves as an important research target for understanding receptor activation, signaling pathways, and downstream effects that may have translational relevance to human health and disease .

What are the most reliable methods for detecting PAR2 expression in rat tissue samples?

Several methodologies can be employed for detecting PAR2 expression in rat tissue samples:

• mRNA detection: Real-time PCR is an effective method for quantifying PAR2 mRNA expression in cardiac and other tissues. As demonstrated in research with PAR2-deficient mice, this approach can confirm the absence of PAR2 expression or quantify expression levels (e.g., 40% reduction after angiotensin II treatment) .

• In situ hybridization: This technique allows visualization of PAR2 expression at the cellular level within tissue sections. It has been successfully used to localize PAR2 expression in vascular smooth muscle cells, interstitial cells, and cardiomyocytes, revealing differential expression patterns across cell types .

• ELISA: Sandwich ELISA kits specific for rat PAR2 provide a sensitive method for quantifying PAR2 levels in serum, plasma, and cell culture supernatants with high specificity. These assays typically offer sensitivity around 4.688 nIU/ml with detection ranges of approximately 7.813-500 nIU/ml .

• Immunohistochemistry: Though challenging due to antibody specificity issues (some researchers report difficulty finding suitable antibodies for mouse PAR2), this method can be valuable when optimized properly .

What are the common challenges in detecting recombinant rat PAR2 and how can they be addressed?

Detecting recombinant rat PAR2 presents several challenges that researchers should anticipate:

• Antibody specificity issues: Finding suitable antibodies for rat PAR2 can be difficult, as noted in studies where researchers failed to locate appropriate antibodies for immunohistochemical detection and had to resort to alternative methods like in situ hybridization . To address this challenge, thorough validation of antibodies with positive and negative controls (e.g., PAR2-deficient tissues) is essential.

• Expression level variations: PAR2 expression can fluctuate in response to stimuli. For instance, angiotensin II treatment has been shown to reduce cardiac PAR2 expression by approximately 40% . This necessitates careful experimental design with appropriate timing for sample collection.

• Cell-type specific expression: PAR2 shows differential expression across cell types, with higher levels in vascular smooth muscle cells and interstitial cells compared to cardiomyocytes . Single-cell resolution techniques or careful microdissection may be required for accurate cell-type specific analysis.

• Protein localization: As a membrane protein, PAR2 extraction and solubilization require specialized protocols to maintain protein integrity and conformation.

How can recombinant rat PAR2 be effectively used in signal transduction studies?

Recombinant rat PAR2 can be utilized in signal transduction studies through several approaches:

• ERK1/2 phosphorylation assays: PAR2 activation influences ERK1/2 phosphorylation, a key signaling pathway in various cellular processes. Immunofluorescence staining for phosphorylated ERK1/2 can quantify this activation in response to PAR2 stimulation or inhibition, as demonstrated in experiments with isolated rat cardiac fibroblasts .

• Pathway inhibitor studies: Using specific PAR2 inhibitors such as AZ3451 (at concentrations of approximately 2 μM) in combination with stimulatory agents like angiotensin II helps elucidate the specific contribution of PAR2 to observed signaling responses .

• TGF-β signaling analysis: PAR2 interactions with TGF-β receptor 1 affect downstream signaling. Measuring Smad2/3 phosphorylation and TGF-β-related gene expression provides insights into this crosstalk. In primary cardiac fibroblasts, PAR2 inhibition has been shown to significantly increase Tgfb2 mRNA expression in unstimulated cells .

• Receptor internalization studies: PAR2 affects the internalization of other receptors, including TGF-β receptor and PAR1, through interactions with caveolin-1. Tracking receptor trafficking can illuminate these regulatory mechanisms .

What are the best experimental models for studying rat PAR2 function in cardiovascular research?

Several experimental models have proven valuable for studying rat PAR2 function in cardiovascular research:

• Angiotensin II-induced hypertension model: Continuous infusion of angiotensin II via osmotic minipumps for 4 weeks creates a reliable hypertension model that can be used to study PAR2's role in cardiac injury, hypertrophy, and fibrosis .

• Primary cardiac fibroblast cultures: Isolated rat cardiac fibroblasts provide an in vitro system for investigating PAR2's role in fibrotic responses and signaling pathways. These cells can be treated with angiotensin II (to mimic hypertensive conditions) and PAR2 inhibitors to assess specific pathway involvement .

• Genetic models: Comparison between wildtype and PAR2-deficient animals enables assessment of PAR2's role in cardiac pathophysiology. These models have revealed distinct phenotypes, with PAR2-deficient mice showing reduced left ventricular hypertrophy but increased cardiac fibrosis in response to angiotensin II .

• Spontaneously hypertensive rats: This model has been used to study PAR2's pro-fibrotic effects in hypertensive heart injury, with interventions such as rivaroxaban (which inhibits activated factor X and may reduce PAR2 activation) reducing cardiac fibrosis .

How does PAR2 interact with other signaling pathways in cardiac hypertrophy and fibrosis?

PAR2 engages in complex interactions with multiple signaling pathways in cardiac pathophysiology:

How can contradictory findings regarding PAR2's role in cardiac fibrosis be reconciled?

The literature presents contradictory findings regarding PAR2's role in cardiac fibrosis, which require careful analysis:

• Temporal considerations: Different experimental endpoints may capture distinct phases of the fibrotic response. For example, the study by Meyer zu Schwabedissen et al. found increased fibrosis in PAR2-deficient mice after 4 weeks of angiotensin II treatment, while Matsuura et al. observed reduced fibrosis in PAR2-deficient mice at just 2 weeks .

• Regional differences: The contradictory findings might be attributed to regional cardiac differences. Meyer zu Schwabedissen et al. examined fibrosis in the left ventricle, while Matsuura et al. focused on the left atrium . These cardiac chambers may exhibit distinct regulatory mechanisms and responses to PAR2 manipulation.

• Compensatory mechanisms: Complete genetic deletion of PAR2 may trigger compensatory adaptations in related pathways that acute pharmacological inhibition does not induce. This could explain why PAR2 antagonist FSLLRY reduced collagen-3 expression in hypertensive models, contrasting with increased fibrosis in PAR2-deficient mice .

• Background strain and model differences: Variations in mouse strains or specific details of model implementation (dose of angiotensin II, duration of treatment) might contribute to discrepant findings, emphasizing the importance of standardized experimental approaches.

To reconcile these contradictions, researchers should consider implementing time-course studies, multiregional cardiac analysis, and comparison of genetic versus pharmacological PAR2 inhibition within the same experimental paradigm.

What are the optimal conditions for expressing and purifying recombinant rat PAR2?

While the search results don't provide specific protocols for expressing and purifying recombinant rat PAR2, general principles for G-protein coupled receptors can be applied with the following considerations:

• Expression systems: Mammalian cell expression systems (e.g., HEK293, CHO cells) typically provide better folding and post-translational modifications for membrane proteins like PAR2 compared to bacterial systems. For functional studies, cells that don't endogenously express PAR2 should be selected to avoid background effects.

• Fusion tags: Addition of affinity tags (His-tag, FLAG-tag) facilitates purification while fluorescent protein fusions (GFP, mCherry) enable tracking of expression and localization. The placement of tags (N-terminal vs. C-terminal) should be carefully considered to avoid interfering with receptor function.

• Solubilization: As a membrane protein, PAR2 requires appropriate detergents for solubilization. Mild detergents (DDM, LMNG) at concentrations above their critical micelle concentration help maintain protein structure and function during extraction.

• Quality control: Multiple methods should be employed to assess the quality of purified recombinant PAR2, including SDS-PAGE, Western blotting with specific antibodies, and functional assays to confirm retained activity.

What considerations are important when designing loss-of-function studies for rat PAR2?

Designing effective loss-of-function studies for rat PAR2 requires careful consideration of several factors:

• Model selection: Both genetic and pharmacological approaches have value. Genetic models (PAR2-deficient rats or mice) provide complete and constitutive receptor elimination, while pharmacological inhibition with agents like AZ3451 (typically used at ~2 μM) or the peptide antagonist FSLLRY offers temporal control over PAR2 inhibition .

• Validation of PAR2 elimination: Thorough validation is essential, typically through real-time PCR to confirm absence of PAR2 mRNA expression in genetic models or functional assays to verify receptor inhibition in pharmacological approaches .

• Control for compensatory mechanisms: Chronic absence of PAR2 in genetic models may trigger compensatory upregulation of related pathways that confound interpretation. Inducible knockout systems or comparison with acute pharmacological inhibition can help address this issue.

• Cell-type specific considerations: Given PAR2's differential expression across cardiac cell types (higher in vascular smooth muscle cells and interstitial cells than in cardiomyocytes), cell-type specific knockout approaches may provide more nuanced insights than global deletion .

• Endpoint selection: The choice of experimental endpoints should reflect PAR2's diverse functions. For cardiac studies, measurements of hypertrophy (heart weight, left ventricular cross-sectional area), fibrosis (Sirius Red staining, collagen IV staining), and molecular signaling (ERK1/2 phosphorylation, TGF-β pathway activation) provide complementary insights .

How do findings from rat PAR2 studies translate to human cardiovascular pathophysiology?

Findings from rat PAR2 studies have several translational implications for human cardiovascular pathophysiology:

• Conserved molecular mechanisms: The PAR2 receptor shows structural and functional conservation across species, suggesting that fundamental mechanistic insights from rat models may apply to human cardiovascular pathophysiology . This conservation supports the translational relevance of findings regarding PAR2's role in inflammation, fibrosis, and hypertrophy.

• Therapeutic targeting: Experimental approaches demonstrating beneficial effects of PAR2 inhibition in rat models inform potential therapeutic strategies for human cardiovascular diseases. For example, findings that PAR2 deficiency reduces left ventricular hypertrophy in response to angiotensin II suggest that PAR2 antagonists might have therapeutic value in hypertensive heart disease .

• Biomarker potential: Understanding PAR2's regulation in response to cardiovascular stress (e.g., 40% reduction in cardiac PAR2 expression after angiotensin II treatment) highlights its potential as a biomarker of cardiovascular pathophysiology . Similar expression patterns in human tissues would support its clinical utility.

• Pathway conservation: The interaction between PAR2 and established pathways in cardiovascular disease (ERK1/2, TGF-β) suggests conserved signaling networks that can guide targeted therapeutic approaches in humans. Particularly, PAR2's modulation of FGF23 expression may have implications for cardiac hypertrophy in human disease .

What are the potential therapeutic applications of targeting PAR2 in cardiovascular diseases?

Based on experimental findings, several potential therapeutic applications for PAR2 targeting in cardiovascular diseases can be identified:

• Anti-hypertrophic strategies: PAR2 deficiency reduces left ventricular hypertrophy in angiotensin II-treated mice, suggesting PAR2 antagonists might limit pathological cardiac hypertrophy in hypertensive heart disease . This approach would be particularly relevant for conditions where inappropriate hypertrophy contributes to heart failure progression.

• Balanced fibrosis modulation: The complex role of PAR2 in cardiac fibrosis requires careful consideration. While some studies show increased fibrosis in PAR2-deficient mice, others demonstrate reduced fibrosis with PAR2 inhibition . Stage-specific or region-specific PAR2 modulation might be necessary to achieve optimal therapeutic outcomes.

• Vascular protection: PAR2's expression in vascular smooth muscle cells and endothelial cells suggests potential applications in vascular protection. Targeted delivery of PAR2 modulators to the vasculature might address vascular remodeling in hypertension and other cardiovascular diseases .

• Combination with existing therapies: PAR2 antagonists might complement established cardiovascular therapies. For example, combining PAR2 inhibition with angiotensin II receptor blockers could potentially provide synergistic benefits by targeting multiple aspects of cardiovascular pathophysiology .

The clinical development of PAR2-targeted therapies will require careful optimization of compound specificity, delivery strategies, and treatment timing to maximize beneficial effects while minimizing potential adverse consequences.

What are the most promising areas for future research using recombinant rat PAR2?

Several promising areas for future research using recombinant rat PAR2 include:

• Temporal dynamics of PAR2 signaling: Investigating the time-dependent effects of PAR2 activation on cardiac hypertrophy and fibrosis would help reconcile conflicting findings in the literature. Sequential analysis at multiple timepoints following angiotensin II treatment could reveal phase-specific PAR2 functions .

• Regional cardiac differences: Comparative studies of PAR2's role in different cardiac chambers (atria vs. ventricles) and regions (epicardium vs. endocardium) would provide more nuanced understanding of its function. This approach could explain why studies examining different cardiac regions have yielded contradictory results regarding PAR2's fibrotic effects .

• Cell-type specific functions: Developing cell-type specific PAR2 knockout or overexpression models would illuminate its differential roles in cardiomyocytes, fibroblasts, vascular smooth muscle cells, and endothelial cells. The observed expression differences across these cell types suggest potentially distinct functions .

• Interaction with non-canonical pathways: Beyond established ERK1/2 and TGF-β pathways, exploration of PAR2's interaction with other signaling networks, particularly those involving FGF23, could reveal novel therapeutic targets. The significant differential regulation of FGF23 between wildtype and PAR2-deficient mice warrants further investigation .

• Receptor crosstalk: Investigating PAR2's interaction with other receptors beyond TGF-β receptor 1, particularly those involved in hypertensive signaling, would provide a more comprehensive understanding of its regulatory role in cardiovascular pathophysiology .

What methodological innovations could advance the study of rat PAR2 function and signaling?

Several methodological innovations could significantly advance the study of rat PAR2 function and signaling:

• CRISPR-based approaches: Development of CRISPR/Cas9 techniques for precise genetic manipulation of PAR2 in rat models, including conditional and inducible knockout systems, would enable more sophisticated functional studies while minimizing compensatory adaptations.

• Single-cell analysis: Application of single-cell transcriptomics and proteomics to PAR2-expressing tissues would provide unprecedented resolution of cell-type specific expression patterns and responses to PAR2 manipulation, building upon the cellular heterogeneity observed with in situ hybridization .

• Advanced imaging techniques: Implementation of super-resolution microscopy and live-cell imaging with fluorescently tagged PAR2 would enable real-time visualization of receptor trafficking, activation, and interaction with other signaling molecules in response to stimuli.

• Phosphoproteomics: Comprehensive phosphoproteomic analysis following PAR2 activation or inhibition would map the full spectrum of downstream signaling events beyond currently studied pathways, potentially identifying novel therapeutic targets.

• Tissue-specific drug delivery: Development of targeted delivery systems for PAR2 modulators to specific cardiac regions or cell types would enable more precise manipulation of PAR2 function in vivo, potentially resolving the apparently contradictory effects observed in different experimental paradigms .

These methodological innovations would collectively advance our understanding of PAR2 biology and accelerate the development of PAR2-targeted therapeutic strategies for cardiovascular diseases.